Jacobio Pharma

Our KRAS G12C inhibitor glecirasib has been granted orphan drug designation (ODD) by the European Medicines Agency (EMA) 👏 Previously, Glecirasib for pancreatic cancer was granted orphan drug designation from FDA in the United States and breakthrough therapy designation from CDE in China. Read more: https://lnkd.in/gQ8EjgqX

Jacobio received IND approval of Pan-KRAS inhibitor JAB-23E73 from FDA. 🎉 KRAS is widely present in a variety of tumor mutations. 23%-25% of cancer patients have KRAS mutations. About 2.7 million tumor patients with KRAS-related mutations are added each year worldwide and are expected to benefit from Pan-KRAS inhibitor. JAB-23E73 can inhibit both the active (“ON”）and inactive (“OFF”) states of KRAS and with no obvious inhibition to HRAS or NRAS. As an oral KRAS inhibitor, JAB-23E73's preclinical data showed good pharmacokinetic profile. 🔗 https://lnkd.in/gEZnbf8S

🌟Jacobio presented efficacy data of PD-L1 expression of KRAS G12C inhibitor glecirasib in combo with SHP2 inhibitor JAB-3312 at 2024 ESMO 🔗 https://lnkd.in/gN7Azz-5 #biotech #KRAS #SHP2 #Jacobio

🔬🎉We are pleased to announce that Jacobio has successfully out-licensed our two clinical assets, SHP2 inhibitor JAB-3312 and KRAS G12C inhibitor glecirasib, to our partner, Allist Pharmaceuticals, for further development and commercialization in China (including mainland China, Hong Kong, Macau, and Taiwan). For more details, visit our website: https://lnkd.in/gy3te6D9  #biotech #outlicensing #kras #SHP2

We are pleased to share that the preclinical research results of our SHP2 inhibitor JAB-3312 were published in the Journal of Medicinal Chemistry. The structure of JAB-3312 was disclosed for the first time. #SHP2 #bitoech #oncology #Jacobio

We are pleased to announce that the first patient dosage in the Phase III Clinical Trial of SHP2 inhibitor JAB-3312 in combination with KRAS G12C inhibitor glecirasib has been completed. #KRAS #SHP2 #NSCLC 

We are pleased to announce that the first patient has been dosed in the Phase I/IIa clinical trial of JAB-30355, a p53 Y220C reactivator, in patients with solid tumors. #p53

We are pleased to announce the appointment of Dr. Michael Ren as the company's Vice President of Chemistry, who will be responsible for drug discovery and chemistry. " Dr. Ren has extensive experience in chemistry. He will further enhance Jacobio’s early R&D capabilities and help us continue to develop the undruggable targets. We welcome his joining," said Dr. Yinxiang Wang, Chairman and CEO of Jacobio Pharma. 

We are pleased to announce the appointment of Dr. Alan Xiao as the company's Vice President of Clinical Pharmacology, who will be based in Boston and lead the Clinical Pharmacology team at Jacobio.   "Dr. Alan Xiao will bring extensive experience in clinical pharmacology research, helping Jacobio Pharma in the global development of its projects. He will further enhance the company's R&D capabilities. We welcome his joining." said Dr. Yinxiang Wang, Chairman and CEO of Jacobio Pharma.   Dr. Alan Xiao obtained his Ph.D. from Rice University, US, and then conducted professional training in clinical pharmacology, advanced pharmacokinetics, and pharmacodynamics at the State University of New York at Buffalo. He has over 20 years of experience in drug development. Prior to working for Jacobio, he worked for many multinational pharmaceutical companies such as Novartis, AstraZeneca, and Merck, and has held management positions in many biotech companies, leading the company's clinical pharmacology capability development.

We are delighted to share that we presented updated data of KRAS G12C inhibitor glecirasib (JAB-21822) in combo with SHP2 inhibitor (JAB-3312) in frontline non-small cell lung cancer patients harboring KRAS G12C mutation.   The cORR of the optimal dose group was 77.4% (24/31), and 54.8% (17/31) of patients had tumors that shrank by more than 50%, achieving deep response.   #cancer #KRAS #SHP2 #biotech #ASCO